Detailed description page of B3Pdb
This page provides detail information of Selected ID b3pdb_0067 |
Primary information | |
---|---|
B3PDB ID | b3pdb_0067 |
Peptide Name | HAVN2 |
PEPTIDE SEQUENCE (1-letter) | SHAVS |
PEPTIDE SEQUENCE (3-letter) | SerHisAlaValSer |
N-terminal modification | NA |
C-terminal modification | NA |
Chemical modification | NA |
Peptide Length | 5 |
Conformation | Cyclic |
Peptide Nature | NA |
Source/Origin of peptide | Chemically synthesized |
SMILES | N[C@@]([H])(CO)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CO)C(=O)O |
Cell Line | NA |
In vitro CONCENTRATION | NA |
In vitro METHOD | NA |
In vitro RESULT | NA |
ANIMAL MODEL | C57BL6 mice |
In vivo CONCENTRATION | NA |
In vivo MODE OF DELIVERY | Intracerebral ventricular |
In vivo METHOD | Mass Spectromtery |
In vivo RESULT | It is able to deliver an IRdye800CW-labeled IgG monoclonal antibody into the brain. |
ACTION | Synthesized novel cyclic peptides are able efectively modulate the BBB to enhance the delivery of mA |
TRANSPORT TYPE | NA |
SUBCELLULAR LOCALISATION | NA |
COMBINATION | Combined with monoclonal antibody |
PHYSICAL CONDITION | NA |
RESPONSE | NA |
RESULT | NA |
LABEL | NA |
PMID | 31683745 |